Jan. 27, 2020—Siemens Healthineers has added the ARK Fentanyl Assay to its testing menu.
The ARK Fentanyl Assay, from ARK Diagnostics, can detect norfentanyl and the parent fentanyl, enabling laboratories to identify more true positives. The assay “extends the detection window to provide the information clinicians need to triage their patients more appropriately,” the company said in a press release. Assays measuring solely the parent fentanyl typically have a shorter window for detection.
The assay is 510(k) cleared and CE marked and is available on the Siemens Atellica Solution, Viva systems, and Dimension and Dimension Vista systems. Using the ARK Fentanyl Assay, opioid testing can be consolidated with other Siemens assays, including oxycodone, buprenorphine, 6-acetylmorphine, methadone, and opiates.